PCVX logo

Vaxcyte (PCVX)

Profile

Full Name

Vaxcyte, Inc.

Ticker Symbol

PCVX

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

June 12, 2020

Indexes

Not included

Website

http://vaxcyte.com

Employees

414

Key Details

Price

$35.24(-1.67%)

Market cap

$4.54B(Mid cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

-

Annual EPS

-$3.80(+8.21% YoY)

PE ratio

-

Next earnings date

May 8, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$35.24
PCVX price is $35.24

30-Day Relative Volume

1.25
PCVX 30-day relative volume is 1.25

Price Performance

Price Today change

-1.67%
PCVX price is down -1.67% today

Price YTD change

-56.95%
PCVX price is down -56.95% since January 1st

Price 1-year change

-44.69%
PCVX price is down -44.69% year-on-year

Price 3-year change

+45.56%
PCVX price is up +45.56% over the past 3 years

Price Range

Price All-time high

$121.06
PCVX price is currently -70.89% below its historical high of $121.06

Price 3-year low

$17.44
PCVX price is currently +102.06% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$4.54B
PCVX market capitalization is $4.54 billion

Market cap 3-year change

+222.86%
PCVX market capitalization is up +222.86% over the past 3 years

Market cap All-time high

$14.67B
PCVX market capitalization is currently -69.08% below its historical high of $14.67 billion

Market cap sector rank

88.61%
PCVX market capitalization is higher than 88.61% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+18.39%
PCVX shares outstanding is up +18.39% year-on-year

Shares Outstanding 3-Year Change

+121.8%
PCVX shares outstanding is up +121.8% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

0.59
PCVX beta is 0.59

200-day SMA

$84.14
PCVX price is currently -58.12% below its 200-day simple moving average

50-day SMA

$54.84
PCVX price is currently -35.74% below its 50-day simple moving average

RSI

39.50
PCVX 14-day relative strength index is 39.50

Volume

1.25
PCVX 30-day relative volume is 1.25

ATR

$3.07
PCVX average true range is $3.07

10-day Historical Volatility

57.11%
PCVX 10-day historical volatility is 57.11%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

-
PCVX annual revenue value is unknown

Revenue Analysts estimate

-
PCVX annual revenue consensus analysts' forecast is unknown

Revenue 1-year change

-
PCVX annual revenue 1-year change is unknown

Revenue Sector rank

-
PCVX annual revenue is unknown

EPS

EPS

-$3.80
PCVX annual earnings per share is -$3.80

EPS Analysts estimate

-$4.40
PCVX annual earnings per share is currently -13.56% lower than the consensus analysts' forecast

EPS 1-year change

+8.21%
PCVX annual earnings per share is up +8.21% year-on-year

EPS Sector rank

23.56%
PCVX annual earnings per share is higher than 23.56% of companies in Healthcare sector

Profit

Gross profit

-
PCVX annual gross profit value is unknown

Gross margin

-
PCVX annual gross profit margin value is unknown

Operating profit

-$569.55M
PCVX annual operating income is -$569.55 million

Operating margin

-
PCVX annual operating profit margin value is unknown

Net income

-$463.93M
PCVX annual net profit is -$463.93 million

Net margin

-
PCVX annual net profit margin value is unknown

Expenses

Total expenses

$569.55M
PCVX annual total expenses is $569.55 million

Operating expenses

$569.55M
PCVX annual total operating expenses is $569.55 million

Cost of goods sold

-
PCVX annual cost of goods sold value is unknown

Selling, general & administrative expenses

$92.90M
PCVX annual SGA is $92.90 million

Depreciation and amortization

$15.85M
PCVX annual depreciation & amortization is $15.85 million

Interest expense

$0.00
PCVX annual interest expense is $0.00

Income tax

-
PCVX annual income tax value is unknown

EBIT & EBITDA

EBIT

-$463.93M
PCVX annual earnings before interest & taxes is -$463.93 million

EBITDA

-$448.08M
PCVX annual EBITDA is -$448.08 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$3.51B
PCVX annual total assets is $3.51 billion

Non current assets

$1.72B
PCVX annual long term assets is $1.72 billion

Current assets

$1.79B
PCVX annual total current assets is $1.79 billion

Cash and cash equivalents

$387.88M
PCVX annual cash & cash equivalents is $387.88 million

Accounts receivable

-
PCVX annual accounts receivable value is unknown

Inventory

-
PCVX annual inventory value is unknown

Liabilities

Total liabilities

$205.50M
PCVX annual total liabilities is $205.50 million

Long term liabilities

$65.32M
PCVX annual total long term liabilities is $65.32 million

Current liabilities

$140.18M
PCVX annual total current liabilities is $140.18 million

Accounts payable

$48.45M
PCVX annual accounts payable is $48.45 million

Debt

Total debt

$71.11M
PCVX annual total debt is $71.11 million

Total debt 1-year change

+143.33%
PCVX annual total debt is up +143.33% year-on-year

Long term debt

$65.22M
PCVX annual long term debt is $65.22 million

Short term debt

$5.89M
PCVX annual short term debt is $5.89 million

Equity & Capital

Shareholders equity

$3.31B
PCVX annual stockholders equity is $3.31 billion

Book value

$3.31B
PCVX annual book value is $3.31 billion

Retained earnings

-$1.39B
PCVX annual retained earnings is -$1.39 billion

Working capital

$1.65B
PCVX annual working capital is $1.65 billion

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$452.63M
PCVX annual cash flow from operations is -$452.63 million

Cash from operations 1-year change

-52.51%
PCVX annual cash flow from operations is down -52.51% year-on-year

Cash from investing

-$2.01B
PCVX annual cash flow from investing activities is -$2.01 billion

Cash from investing 1-year change

-159.36%
PCVX annual cash flow from investing activities is down -159.36% year-on-year

Cash from financing

$2.45B
PCVX annual cash flow from financing activities is $2.45 billion

Cash from financing 1-year change

+282.69%
PCVX annual cash flow from financing activities is up +282.69% year-on-year

CAPEX

CAPEX

-
PCVX annual capital expenditures value is unknown

CAPEX 1-year change

-
PCVX annual capital expenditures 1-year change is unknown

Free Cash Flow

Free cash flow

-$571.79M
PCVX annual free cash flow is -$571.79 million

Free cash flow 1-year change

-56.8%
PCVX annual free cash flow is down -56.8% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

-
PCVX annual gross profit margin value is unknown

Operating margin

-
PCVX annual operating profit margin value is unknown

Net margin

-
PCVX annual net profit margin value is unknown

ROA & ROE

ROA

-13.21%
PCVX annual return on assets is -13.21%

ROE

-14.03%
PCVX annual return on equity is -14.03%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
PCVX price to earnings ratio value is unknown

PE ratio Sector rank

-
PCVX price to earnings ratio is unknown

PB Ratio

PB ratio

1.37
PCVX price to book ratio is 1.37

PB ratio Sector rank

48.53%
PCVX price to book ratio is higher than 48.53% of companies in Healthcare sector

PS Ratio

PS ratio

-
PCVX price to sales ratio value is unknown

PS ratio Sector rank

-
PCVX price to sales ratio is unknown

Enterprise value

Enterprise value

$4.22B
PCVX enterprise value is $4.22 billion

Enterprise value Sector rank

87.37%
PCVX enterprise value is higher than 87.37% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-9.42
PCVX EV/EBITDA is -9.42

EV/EBITDA Sector rank

13.41%
PCVX EV/EBITDA is higher than 13.41% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

12.75
PCVX annual current ratio is 12.75

Quick ratio

-
PCVX annual quick ratio value is unknown

Leverage

Debt to equity

0.02
PCVX annual debt to equity ratio is 0.02

Interest coverage ratio

-
PCVX annual interest coverage ratio value is unknown

Risk & Stability

Piotroski F-Score

-
PCVX piotroski f-score value is unknown

Altman Z-Score

-
PCVX altman z-score value is unknown

Analyst ratings

Recent major analysts updates

Apr 22, 25 Cantor Fitzgerald
Overweight
Apr 8, 25 Needham
Buy
Apr 1, 25 Needham
Buy
Apr 1, 25 Goldman Sachs
Buy
Apr 1, 25 B of A Securities
Buy
Mar 12, 25 Guggenheim
Buy
Feb 26, 25 Needham
Buy
Feb 26, 25 Guggenheim
Buy
Feb 24, 25 BTIG
Buy
Feb 11, 25 Needham
Buy

Institutional Ownership

Similar stocks

ALKS logo
Alkermes (ALKS)
INSP logo
Inspire Medical Systems (INSP)
ELAN logo
Elanco Animal Health Incorporated (ELAN)
GRFS logo
Grifols SA (GRFS)
ITGR logo
Integer Holdings (ITGR)
IONS logo
Ionis Pharmaceuticals (IONS)
KRYS logo
Krystal Biotech (KRYS)
CYTK logo
Cytokinetics Incorporated (CYTK)
RYTM logo
Rhythm Pharmaceuticals (RYTM)
  • What is the ticker symbol for Vaxcyte?
  • Does Vaxcyte pay dividends?
  • What sector is Vaxcyte in?
  • What industry is Vaxcyte in?
  • What country is Vaxcyte based in?
  • When did Vaxcyte go public?
  • Is Vaxcyte in the S&P 500?
  • Is Vaxcyte in the NASDAQ 100?
  • Is Vaxcyte in the Dow Jones?
  • When was Vaxcyte's last earnings report?
  • When does Vaxcyte report earnings?
  • Should I buy Vaxcyte stock now?

What is the ticker symbol for Vaxcyte?

The ticker symbol for Vaxcyte is NASDAQ:PCVX

Does Vaxcyte pay dividends?

No, Vaxcyte does not pay dividends

What sector is Vaxcyte in?

Vaxcyte is in the Healthcare sector

What industry is Vaxcyte in?

Vaxcyte is in the Biotechnology industry

What country is Vaxcyte based in?

Vaxcyte is headquartered in United States

When did Vaxcyte go public?

Vaxcyte's initial public offering (IPO) was on June 12, 2020

Is Vaxcyte in the S&P 500?

No, Vaxcyte is not included in the S&P 500 index

Is Vaxcyte in the NASDAQ 100?

No, Vaxcyte is not included in the NASDAQ 100 index

Is Vaxcyte in the Dow Jones?

No, Vaxcyte is not included in the Dow Jones index

When was Vaxcyte's last earnings report?

Vaxcyte's most recent earnings report was on Feb 25, 2025

When does Vaxcyte report earnings?

The next expected earnings date for Vaxcyte is May 8, 2025

Should I buy Vaxcyte stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page